• On April 3, 2026, Takeda Pharmaceutical notified Denali Therapeutics that it will terminate their 2018 collaboration to co-develop and co-commercialize DNL593 (PTV:PGRN), with all program rights reverting to Denali and no further financial obligations owed to Takeda.
• The decision, driven by Takeda’s internal priorities rather than efficacy or safety concerns, leaves Denali with full control of a Phase 1/2 asset that has already shown dose-dependent cerebrospinal fluid progranulin increases and an encouraging tolerability profile in early data.
• We’ll now examine how Denali’s regained full ownership of DNL593 shapes its investment narrative and future development flexibility.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

What Is Denali Therapeutics' Investment Narrative?

To own Denali Therapeutics, you really have to believe that its blood-brain barrier “Transport Vehicle” platform can translate into multiple meaningful CNS therapies, not just a single drug win. In the near term, the AVLAYAH launch for Hunter syndrome and progress across partnered LRRK2 and RIPK1 programs remain the key catalysts, while the company continues to run large losses with no clear path to profitability. The Takeda exit from DNL593 is an important twist, but it looks more like a shift in control than a thesis-breaking setback, given the lack of efficacy or safety concerns and Denali’s regained flexibility over a Phase 1/2 asset. That said, full ownership also concentrates development costs and execution risk back on Denali’s balance sheet.

Our valuation report unveils the possibility Denali Therapeutics' shares may be trading at a premium.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community cluster tightly between about US$33.7 and US$36.2 per share, underscoring how differently individuals can frame Denali against its high cash burn and newly regained DNL593 ownership. You can compare these community views with the company’s dependence on clinical and regulatory milestones that now carry even more weight after the Takeda decision.

Explore 2 other fair value estimates on Denali Therapeutics - why the stock might be worth as much as 75% more than the current price!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Denali Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Denali Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Denali Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.